Biodexa Pharmaceuticals Secures $17 Million CPRIT Grant Funding
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company focused on innovation and acquisitions, has reached a major milestone in its mission to tackle unmet medical needs. They’ve successfully completed a final match payment of $3.0 million, allowing access to a total of $17 million from the Cancer Prevention Research Institute of Texas (CPRIT).
Why CPRIT Funding Matters
For Biodexa, CPRIT funding is crucial as it will significantly aid the advancement of their Phase 3 registrational study of eRapa, targeting Familial Adenomatous Polyposis (FAP). This inherited condition results in multiple precancerous polyps forming in the gastrointestinal (GI) tract, which greatly raises the risk of colon cancer. Currently, there are no approved treatments for the approximately 100,000 individuals affected by FAP in the U.S. and Europe, making this research all the more urgent.
Message from the CEO on the Funding
Stephen Stamp, CEO and CFO of Biodexa, shared his excitement regarding this essential funding: “With the completion of the second and final match payment, we now have direct access to the remainder of the $17 million CPRIT grant, which is intended to fund our upcoming Phase 3 study of eRapa.” His comments highlight the strategic importance of this funding for advancing their clinical trials.
Insights from the Phase 2 Trial and What Lies Ahead
Biodexa also reported encouraging results from a recent 12-month Phase 2 clinical trial of eRapa, which showed a 17 percent median reduction in overall polyp burden among participants. The trial also revealed an impressive overall non-progression rate of 75 percent. These positive findings pave the way for the much-anticipated Phase 3 trial, expected to start enrollment soon.
About eRapa's Development
eRapa is Biodexa's unique oral formulation of rapamycin, recognized for its potency as an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR is vital for managing cellular metabolism and growth, both key elements in the development of tumors. Biodexa's dedication to eRapa underscores its commitment to providing solutions for patients facing serious health challenges.
CPRIT's Mission and Its Impact
The Cancer Prevention and Research Institute of Texas (CPRIT) was established to lead Texas's fight against cancer. Since it began, the institute has allocated over $3 billion in grants for various Texas-based research initiatives aimed at both cancer prevention and the development of innovative drugs. This latest funding will support scientific research that has the potential to bring about groundbreaking advancements in cancer treatment.
Biodexa's Broader Development Goals
Beyond eRapa, Biodexa Pharmaceuticals is progressing on other important projects. These include tolimidone, being developed for type 1 diabetes, and MTX110, which is under investigation for aggressive and rare brain cancers. Each of these programs reflects Biodexa’s commitment to addressing serious healthcare needs and helping patients around the globe.
Looking Ahead: Biodexa's Future Plans
Biodexa Pharmaceuticals is dedicated to more than one avenue of treatment. Their extensive pipeline illustrates a broader vision to innovate across multiple therapeutic areas. This ambition is bolstered by their proprietary drug delivery technologies designed to enhance how medications are delivered and distributed in the body.
With their headquarters and R&D operations located in Cardiff, UK, Biodexa is well-positioned to utilize its expertise and resources to advance its clinical programs. As the company continues to seek new opportunities, it remains committed to playing a key role in transforming the therapeutic landscape for patients with pressing health needs.
Frequently Asked Questions
What is the significance of the $3.0 million match payment?
The $3.0 million match payment allows Biodexa to access the remaining funds from a total of $17 million grant from CPRIT, crucial for advancing their research initiatives.
What is eRapa targeting?
eRapa is being developed as a treatment option for Familial Adenomatous Polyposis (FAP), a genetic disorder leading to precancerous polyp growth.
When is the Phase 3 trial for eRapa expected to start?
The Phase 3 registrational trial for eRapa is anticipated to begin enrollment early next year following the positive results from the Phase 2 study.
What other products is Biodexa developing?
Besides eRapa, Biodexa is developing tolimidone for type 1 diabetes and MTX110 for rare brain cancer conditions.
Where is Biodexa Pharmaceuticals based?
Biodexa Pharmaceuticals is headquartered in Cardiff, UK, where it operates its research and development facilities.
